Trofinetide

Drug Profile

Trofinetide

Alternative Names: G-2Me-PE; Glycyl-2-methyl-L-prolyl-L-glutamic acid; Glycyl-L-2-methylprolyl-L-glutamic acid; NNZ-2566

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator Neuren Pharmaceuticals
  • Developer Neuren Pharmaceuticals; Rettsyndrome.org; Walter Reed Army Institute of Research
  • Class Glutamates; Neuropeptides; Neuroprotectants; Oligopeptides; Pyrrolidines; Small molecules
  • Mechanism of Action Cytokine inhibitors; Glial cell modulators; Neuropeptide receptor modulators; Synaptic transmission modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rett syndrome; Fragile X syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Brain injuries; Fragile X syndrome; Rett syndrome
  • Preclinical Autistic disorder; Multiple sclerosis

Most Recent Events

  • 01 Jan 2017 Neuren Pharmaceuticals completes a phase-II trial in Rett syndrome (In children, In adolescents) in USA (PO) (NCT02715115)
  • 22 Jun 2016 Neuren receives Notice of Grant for trofinetide in Australia
  • 22 Jun 2016 Neuren has patents pending for trofinetide in USA, Europe, Canada, Brazil and Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top